Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38299476/
The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.
This review explores GLP-1 receptor-binding medications for obesity, assessing their mechanisms, efficacy, and safety, highlighting key treatments like retatrutide, tirzepatide, and semaglutide, with an emphasis on long-term outcomes.
Share
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39295512/
The rapid and widespread clinical adoption of highly effective incretin-mimetic drugs (IMDs), particularly semaglutide and tirzepatide, for the treatment of obesity has outpaced the updating of clinical practice guidelines. Consequently,...
Incretin-mimetic drugs for obesity may cause muscle loss, impacting health. Adequate protein, micronutrients, and resistance training are essential to preserve muscle mass, optimize therapy, and minimize risks in patients.
Share
Pharmacologic Treatment of Overweight and Obesity in Adults - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/25905267/
Obesity pharmacotherapy has evolved significantly over the past 60 years. Today, six anti-obesity medications (AOMs) are approved by the Federal Drug Administration (FDA) for the long-term treatment of obesity. Similar...
Obesity pharmacotherapy has evolved with six FDA-approved medications for long-term weight management, recommended for individuals with BMI ≥30 or ≥27 with comorbidities, alongside lifestyle modifications for effective treatment.
Share
Female obesity: clinical and psychological assessment toward the best treatment - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38765954/
Obesity is a heterogeneous condition which results from complex interactions among sex/gender, sociocultural, environmental, and biological factors. Obesity is more prevalent in women in most developed countries, and several clinical...
This review highlights gender differences in obesity prevalence, contributing factors, clinical complications, psychological challenges, and responses to treatments, including new anti-obesity drugs, emphasizing the need for gender-specific approaches.
Share
Obesity in untreated early rheumatoid arthritis reduces treatment response likelihood across therapies, with higher disease activity despite similar baselines, highlighting BMI's impact on clinical outcomes over 48 weeks.
Share